Back to diseases

Disease hub

Renal Cell Carcinoma

Open Targets catalogue label: renal cell carcinoma

Structured disease–target and disease–drug rows, trial registry mirrors, and linked research signals appear here when they are indexed to this hub key. Sparse pages are expected for newer routes — this is not a claim about biological evidence absence.

Data: Live structured evidence (Supabase)

Source catalogue
Imported rows
Explorer-eligible
Targets w/ drugs
Also indexed as

renal cell carcinoma · EFO_0000681 · kidney adenocarcinoma · RCC · hypernephroma · renal cell carcinoma (disease) · renal cell adenocarcinoma · GARD:13215 · Orphanet:217071 · OMIM:300854 · SCTID:702391001 · MONDO:0005086 · NORD:1657 · ICD9:189.0 · UMLS:C0007134 · DOID:4450 · MedDRA:10067946 · MedDRA:10020681 · ONCOTREE:RCC · EFO:0000681 · NCIT:C9385 · GARD:0013215 · HP:0005584 · MEDGEN:766 · OMIM:144700 · NANDO:2200045 · MESH:D002292

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Imported evidence rows

Source evidence rows, not unique targets.

Explorer-eligible targets

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.